Altimmune, Inc. Common Stock
ALTAltimmune, Inc. is a biotechnology company focused on developing immunotherapeutic solutions and vaccines for infectious diseases, cancer, and metabolic disorders. The company leverages innovative technology platforms to create treatments aiming to enhance immune responses and improve patient outcomes.
Company News
The global biodefense market is projected to grow from USD 16.81 billion in 2024 to USD 32.87 billion by 2034, driven by advancements in biotechnology, increased government funding, and growing awareness of biological threats.
Faruqi & Faruqi is investigating potential claims against Altimmune after its stock price dropped 53.2% following disappointing Phase 2b MASH trial results for Pemvidutide, where statistical significance was not achieved.
A class action lawsuit has been filed against Altimmune, alleging the company made false and misleading statements about its Pemvidutide trial results in the MASH Phase 2b study, with claims of overstated efficacy and downplaying of statistical significance.
Rosen Law Firm alerts Altimmune investors about a securities class action lawsuit regarding misleading information about the IMPACT Phase 2b MASH trial results, with an October 6, 2025 deadline to join the action.
The Schall Law Firm is pursuing a class action lawsuit against Altimmune for allegedly making false and misleading statements about its drug candidate Pemvidutide, which failed to achieve statistically significant results in its Phase 2B MASH trial.
